Amgen Drug for Secondary Hyperparathyroidism Shows PromiseAmgen Drug for Secondary Hyperparathyroidism Shows Promise

An experimental drug to reduce excess parathyroid hormone levels in patients with chronic kidney disease succeeded in meeting the primary and secondary goals of a Phase III study, Amgen Inc said. Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Nephrology News Source Type: news